Cargando…

High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy

BACKGROUND: Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Ulrike, Gerum, Sabine, Roeder, Falk, Münch, Stefan, Combs, Stephanie E, Philipp, Alexander B, De Toni, Enrico N, Kirstein, Martha M, Vogel, Arndt, Mogler, Carolin, Haller, Bernhard, Neumann, Jens, Braren, Rickmer F, Makowski, Marcus R, Paprottka, Philipp, Guba, Markus, Geisler, Fabian, Schmid, Roland M, Umgelter, Andreas, Ehmer, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240047/
https://www.ncbi.nlm.nih.gov/pubmed/34239274
http://dx.doi.org/10.3748/wjg.v27.i24.3630
_version_ 1783715137418428416
author Bauer, Ulrike
Gerum, Sabine
Roeder, Falk
Münch, Stefan
Combs, Stephanie E
Philipp, Alexander B
De Toni, Enrico N
Kirstein, Martha M
Vogel, Arndt
Mogler, Carolin
Haller, Bernhard
Neumann, Jens
Braren, Rickmer F
Makowski, Marcus R
Paprottka, Philipp
Guba, Markus
Geisler, Fabian
Schmid, Roland M
Umgelter, Andreas
Ehmer, Ursula
author_facet Bauer, Ulrike
Gerum, Sabine
Roeder, Falk
Münch, Stefan
Combs, Stephanie E
Philipp, Alexander B
De Toni, Enrico N
Kirstein, Martha M
Vogel, Arndt
Mogler, Carolin
Haller, Bernhard
Neumann, Jens
Braren, Rickmer F
Makowski, Marcus R
Paprottka, Philipp
Guba, Markus
Geisler, Fabian
Schmid, Roland M
Umgelter, Andreas
Ehmer, Ursula
author_sort Bauer, Ulrike
collection PubMed
description BACKGROUND: Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tumor growth. Transarterial chemoembolization (TACE) and less commonly stereotactic body radiation therapy (SBRT) or a combination of TACE and SBRT, are used as bridging therapies in LT. However, it remains unclear if one of those treatment options is superior. The analysis of explant livers after transplantation provides the unique opportunity to investigate treatment response by histopathology. AIM: To analyze histopathological response to a combination of TACE and SBRT in HCC in comparison to TACE or SBRT alone. METHODS: In this multicenter retrospective study, 27 patients who received liver transplantation for HCC were analyzed. Patients received either TACE or SBRT alone, or a combination of TACE and SBRT as bridging therapy to liver transplantation. Liver explants of all patients who received at least one TACE and/or SBRT were analyzed for the presence of residual vital tumor tissue by histopathology to assess differences in treatment response to bridging therapies. Statistical analysis was performed using Fisher-Freeman-Halton exact test, Kruskal-Wallis and Mann-Whitney-U tests. RESULTS: Fourteen patients received TACE only, four patients SBRT only, and nine patients a combination therapy of TACE and SBRT. There were no significant differences between groups regarding age, sex, etiology of underlying liver disease or number and size of tumor lesions. Strikingly, analysis of liver explants revealed that almost all patients in the TACE and SBRT combination group (8/9, 89%) showed no residual vital tumor tissue by histopathology, whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response (0/14, 0% and 1/4, 25%, respectively, P value < 0.001). CONCLUSION: Our data suggests that a combination of TACE and SBRT increases the rate of complete histopathological response compared to TACE or SBRT alone in bridging to liver transplantation.
format Online
Article
Text
id pubmed-8240047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-82400472021-07-07 High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy Bauer, Ulrike Gerum, Sabine Roeder, Falk Münch, Stefan Combs, Stephanie E Philipp, Alexander B De Toni, Enrico N Kirstein, Martha M Vogel, Arndt Mogler, Carolin Haller, Bernhard Neumann, Jens Braren, Rickmer F Makowski, Marcus R Paprottka, Philipp Guba, Markus Geisler, Fabian Schmid, Roland M Umgelter, Andreas Ehmer, Ursula World J Gastroenterol Retrospective Study BACKGROUND: Liver transplantation (LT) presents a curative treatment option in patients with early stage hepatocellular carcinoma (HCC) who are not eligible for resection or ablation therapy. Due to a risk of up 30% for waitlist drop-out upon tumor progression, bridging therapies are used to halt tumor growth. Transarterial chemoembolization (TACE) and less commonly stereotactic body radiation therapy (SBRT) or a combination of TACE and SBRT, are used as bridging therapies in LT. However, it remains unclear if one of those treatment options is superior. The analysis of explant livers after transplantation provides the unique opportunity to investigate treatment response by histopathology. AIM: To analyze histopathological response to a combination of TACE and SBRT in HCC in comparison to TACE or SBRT alone. METHODS: In this multicenter retrospective study, 27 patients who received liver transplantation for HCC were analyzed. Patients received either TACE or SBRT alone, or a combination of TACE and SBRT as bridging therapy to liver transplantation. Liver explants of all patients who received at least one TACE and/or SBRT were analyzed for the presence of residual vital tumor tissue by histopathology to assess differences in treatment response to bridging therapies. Statistical analysis was performed using Fisher-Freeman-Halton exact test, Kruskal-Wallis and Mann-Whitney-U tests. RESULTS: Fourteen patients received TACE only, four patients SBRT only, and nine patients a combination therapy of TACE and SBRT. There were no significant differences between groups regarding age, sex, etiology of underlying liver disease or number and size of tumor lesions. Strikingly, analysis of liver explants revealed that almost all patients in the TACE and SBRT combination group (8/9, 89%) showed no residual vital tumor tissue by histopathology, whereas TACE or SBRT alone resulted in significantly lower rates of complete histopathological response (0/14, 0% and 1/4, 25%, respectively, P value < 0.001). CONCLUSION: Our data suggests that a combination of TACE and SBRT increases the rate of complete histopathological response compared to TACE or SBRT alone in bridging to liver transplantation. Baishideng Publishing Group Inc 2021-06-28 2021-06-28 /pmc/articles/PMC8240047/ /pubmed/34239274 http://dx.doi.org/10.3748/wjg.v27.i24.3630 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Bauer, Ulrike
Gerum, Sabine
Roeder, Falk
Münch, Stefan
Combs, Stephanie E
Philipp, Alexander B
De Toni, Enrico N
Kirstein, Martha M
Vogel, Arndt
Mogler, Carolin
Haller, Bernhard
Neumann, Jens
Braren, Rickmer F
Makowski, Marcus R
Paprottka, Philipp
Guba, Markus
Geisler, Fabian
Schmid, Roland M
Umgelter, Andreas
Ehmer, Ursula
High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
title High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
title_full High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
title_fullStr High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
title_full_unstemmed High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
title_short High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
title_sort high rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240047/
https://www.ncbi.nlm.nih.gov/pubmed/34239274
http://dx.doi.org/10.3748/wjg.v27.i24.3630
work_keys_str_mv AT bauerulrike highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT gerumsabine highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT roederfalk highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT munchstefan highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT combsstephaniee highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT philippalexanderb highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT detonienricon highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT kirsteinmartham highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT vogelarndt highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT moglercarolin highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT hallerbernhard highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT neumannjens highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT brarenrickmerf highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT makowskimarcusr highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT paprottkaphilipp highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT gubamarkus highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT geislerfabian highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT schmidrolandm highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT umgelterandreas highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy
AT ehmerursula highrateofcompletehistopathologicalresponseinhepatocellularcarcinomapatientsaftercombinedtransarterialchemoembolizationandstereotacticbodyradiationtherapy